Cargando…
SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
BACKGROUND: Itraconazole (ITZ) is an effective agent when used as primary invasive fungal disease (IFD) prophylaxis, but is limited by drug tolerability and variability in serum concentrations. A new formulation, SUBA-itraconazole (for “super bioavailability”; S-ITZ), addresses the limitations of co...
Autores principales: | Lindsay, Julian, Othman, Jad, Kong, Yvonne, Yip, Annie, Van Hal, Sebastiaan, Larsen, Stephen, Bryant, Christian, Gibson, John, Kerridge, Ian, Fay, Keith, Stevenson, William, Arthur, Chris, Chen, Sharon C A, Kong, David C M, Greenwood, Matthew, Pergam, Steven A, Liu, Catherine, Slavin, Monica A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088511/ https://www.ncbi.nlm.nih.gov/pubmed/35559121 http://dx.doi.org/10.1093/ofid/ofab502 |
Ejemplares similares
-
1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data
por: Lindsay, Julian, et al.
Publicado: (2018) -
Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011) -
120. An open-label comparative trial of SUBA-itraconazole (SUBA) versus conventional itraconazole (c-itra) for treatment of proven and probable endemic mycoses (MSG-15): a pharmacokinetic (PK) and adverse Event (AE) analysis
por: Pappas, Peter G, et al.
Publicado: (2021) -
144. MSG-15: Pharmacokinetic (PK), Adverse Events (AEs), and Tolerability Data from an Open Label Randomized Clinical Trial (RCT) Comparing Oral Suba-itraconazole (SUBA-ITC) to Conventional Itraconazole (C-ITC) for Treatment of Endemic Mycosis (EM)
por: Pappas, Peter G, et al.
Publicado: (2020) -
Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)